✦ LIBER ✦

Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma

Book ID: 116588268
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 47 KB
Volume: 66
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2011.11.024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Brentuximab Vedotin (SGN-35) in Patients

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

✍ Pro, B.; Advani, R.; Brice, P.; Bartlett, N. L.; Rosenblatt, J. D.; Illidge, T.; 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 395 KB

Extended retreatment with brentuximab ve

Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma

✍ Foyil, Kelley V.; Kennedy, Dana A.; Grove, Laurie E.; Bartlett, Nancy L.; Cashen 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 229 KB

Efficacy of Brentuximab Vedotin and Othe

Efficacy of Brentuximab Vedotin and Other Treatments in Patients with Relapsed or Refractory (RR) Systemic Anaplastic Large-Cell Lymphoma (SALCL): A Systematic Review

✍ Bonthapally, V.; Yang, H.; Macalalad, A.R.; Wu, E.Q.; Lutes, R.; Shonukan, O.; C 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Brentuximab Vedotin: A Review of Its Use

Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure

✍ Garnock-Jones, Karly P. 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 469 KB